KYTX Key Statistics, Chart & Performance
The current stock price of KYTX is 9.4 USD. In the past month the price increased by 22.4%. In the past year, price increased by 135.59%.
KYTX Latest News, Press Relases and Analysis
KYTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Info
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 129
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What does KYTX do?
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Can you provide the latest stock price for KYVERNA THERAPEUTICS INC?
The current stock price of KYTX is 9.4 USD. The price increased by 4.56% in the last trading session.
What is the dividend status of KYVERNA THERAPEUTICS INC?
KYTX does not pay a dividend.
What is the ChartMill rating of KYVERNA THERAPEUTICS INC stock?
KYTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for KYTX stock?
12 analysts have analysed KYTX and the average price target is 28.76 USD. This implies a price increase of 206% is expected in the next year compared to the current price of 9.4.
What is KYVERNA THERAPEUTICS INC worth?
KYVERNA THERAPEUTICS INC (KYTX) has a market capitalization of 411.72M USD. This makes KYTX a Small Cap stock.
What is the Short Interest ratio of KYVERNA THERAPEUTICS INC (KYTX) stock?
The outstanding short interest for KYVERNA THERAPEUTICS INC (KYTX) is 9.15% of its float.
KYTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KYTX. When comparing the yearly performance of all stocks, KYTX is one of the better performing stocks in the market, outperforming 96.99% of all stocks.
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KYTX. KYTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -3.73. The EPS increased by 87.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.02% | ||
| ROE | -105.95% | ||
| Debt/Equity | 0 |
KYTX Forecast & Estimates
12 analysts have analysed KYTX and the average price target is 28.76 USD. This implies a price increase of 206% is expected in the next year compared to the current price of 9.4.